Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice

BACKGROUND: Though the precise cause(s) of Alzheimer’s disease (AD) remain unknown, there is strong evidence that decreased clearance of β-amyloid (Aβ) from the brain can contribute to the disease. Therapeutic strategies to promote natural Aβ clearance mechanisms, such as the protein apolipoprotein-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: LaClair, Katherine D, Manaye, Kebreten F, Lee, Dexter L, Allard, Joanne S, Savonenko, Alena V, Troncoso, Juan C, Wong, Philip C
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Short Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3693923/
https://ncbi.nlm.nih.gov/pubmed/23764200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1326-8-18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados